Compare SGP & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGP | OCSL |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | SGP | OCSL |
|---|---|---|
| Price | $22.52 | $10.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $45.00 | $13.10 |
| AVG Volume (30 Days) | 100.8K | ★ 750.4K |
| Earning Date | 03-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 14.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.31 |
| P/E Ratio | ★ N/A | $186.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.41 | $10.63 |
| 52 Week High | $30.56 | $15.63 |
| Indicator | SGP | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 31.50 | 38.92 |
| Support Level | N/A | $10.63 |
| Resistance Level | $29.83 | $13.89 |
| Average True Range (ATR) | 1.78 | 0.25 |
| MACD | -0.39 | 0.03 |
| Stochastic Oscillator | 10.49 | 38.14 |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.